GOSS - Gossamer Bio

-

$undefined

N/A

(N/A)

Gossamer Bio NasdaqGS:GOSS Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.

Location: 3115 Merryfield Row, San Diego, CA, 92121, United States | Website: https://www.gossamerbio.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

146.9M

Cash

294.5M

Avg Qtr Burn

-867K

Short % of Float

5.48%

Insider Ownership

3.51%

Institutional Own.

75.48%

Qtr Updated

12/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Seralutinib (GB002) (Inhaled PDGF receptor kinase inhibitor) Details
Rare diseases, Pulmonary arterial hypertension, Lung disease

Phase 3

Data readout

Seralutinib (GB002) Details
Lung disease, Pulmonary hypertension associated with interstitial lung disease

Phase 3

Initiation

Failed

Discontinued

GB1275 (Oral CD11b modulator) Details
Solid tumor/s, Esophageal cancer, Cancer, Gastric cancer

Failed

Discontinued

Failed

Discontinued